NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Talphera Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Talphera is a specialty pharmaceutical company developing therapies for medically supervised settings. Its primary focus is Niyad, a nafamostat formulation for regional anticoagulation during continuous renal replacement therapy, and LTX-608 for intravenous infusion to treat disseminated intravascular coagulation, acute respiratory distress syndrome, and acute pancreatitis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Talphera Inc stock.
Not valued: We cannot value this company yet.
All 82 Drug Manufacturers - Specialty & Generic stocks
33 more in this industry show a wider margin of safety.
We do not publish a verdict on TLPH yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.